Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age≥18 years。
Histology confirmed prostate cancer.
Risk stratification, localised disease including patients with low-risk(cT1-T2a，PSA \<10ng/mL，Gleason score≤6) who refuse active surveillance, favorable or unfavorable intermediate-risk and selected high-risk(cT2b-T3a or minimally T3b，PSA 10-40ng/mL，Gleason score 7-8) disease.
Oligo-metastatic disease including patients with prostate in-situ and oligometastatic disease (no limit to mets number and organs, with all metastatic foci can be safely treated by radical SBRT dose)
ECOG 0-2
Postate gland volume ≤100cc
IPSS score of \<18
Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed
You may not be if
Contraindications to MRI.
TURP within the past 6 months
Ulcerative colitis, Crohn's Disease, ataxia telangiectasia, or systemic lupus erythematosus
Previous pelvic irradiation
Refuse contraception
Clareo Health | MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
